Xeris Pharmaceuticals today said it has launched its Gvoke HypoPen glucagon injection to treat severe hypoglycemia. The autoinjector is designed to treat severe hypoglycemia in adults and children with diabetes that are ages two years and older. The premixed autoinjector has no visible needle and has a reliable delivery method. According to the company, 99% […]
Abbott, Tandem seal deal to combine CGM, insulin delivery tech
Abbott (NYSE:ABT) and Tandem Diabetes Care (NSDQ:TNDM) announced today that they have completed their agreement to combine the former’s glucose-sensing technology with the latter’s insulin delivery systems. The deal, announced in October, will combine Abbott’s Freestyle Libre CGM with Tandem’s t:slim X2 pump to monitor glucose without fingersticks. The agreement covers the technical development of device integration […]
Insulet installs thousands of solar panels at global HQ
Insulet (NSDQ:PODD) announced today that its corporate headquarters and manufacturing facility will be powered by solar-based, renewable energy. The Acton, Mass.-based facility is set to turn to the new energy source, beginning this week. The company covered its 58,000 square-foot manufacturing facility with approximately 2,800 solar panels to, during optimal climate conditions, generate enough energy to […]
Tandem Diabetes Care acquires Sugarmate mobile app
Tandem Diabetes Care (NSDQ:TNDM) said today that it has purchased Sugarmate — as mobile app that helps people better manage their diabetes. Financial terms of the deal were not disclosed. Nearly 30,000 people relying on insulin pumps or multiple daily injections presently use the Sugarmate app. Sugarmate cofounder Josh Juster will join Tandem as a VP […]
Tandem Diabetes Care wins expanded FDA indication for insulin pump
Tandem Diabetes Care (NSDQ:TNDM) announced today that it won an expanded pediatric indication from the FDA for its t:slim X2 insulin pump. The t:slim X2 with Control-IQ technology won FDA clearance for controlling Type 1 diabetes in December, which was followed by a commercial launch in the U.S. the next month. Tandem touts t:slim X2 with […]
Abbott, Medtronic go head-to-head at ADA conference
Major medtech companies vied for the biggest news splash at this year’s annual meeting of the American Diabetes Association, announcing promising results from studies of patients who used their latest diabetes technology. The virtual 80th Annual American Diabetes Association Virtual Scientific Sessions, which runs through Tuesday, so far has featured news out of Abbott (NYSE:ABT) and Medtronic (NYSE:MDT) and several smaller […]
Medtronic touts results of latest MiniMed studies at ADA
The latest generation of the Medtronic (NYSE:MDT) MiniMed insulin pump met both safety and glycemic endpoints in a study presented today at the American Diabetes Association’s virtual annual conference. The MiniMed 780G closed-loop system is indicated for treating Type 1 diabetes in people aged 7 to 80 years old. It is designed to automate the delivery of […]
Former Eli Lilly researcher joins Bigfoot Biomedical as chief medical officer
Bigfoot Biomedical has brought on Dr. Jim Malone — a 21-year clinical research veteran at Eli Lilly & Co. — as its chief medical officer, the diabetes treatment tech company said today. Malone, an endocrinologist specializing in diabetes, also spent 12 years in clinical practice. “Jim’s blended experience in medical practice and device development bring […]
Medtronic lands CE Mark for MiniMed 780G insulin pump
Medtronic (NYSE:MDT) announced today that it received CE Mark approval in Europe for its MiniMed 790G next-generation insulin pump. The closed-loop insulin pump system is indicated for treating Type 1 diabetes in people aged 70 to 80 years old. It uses Medtronic’s SmartGuard algorithm to automate the delivery of basal insulin and correction boluses every five […]
Insulet resumes next-gen Omnipod pivotal study following software issues
Insulet (NSDQ:PODD) today said it has resumed its pivotal study of its next-generation Omnipod Insulin Management System after pausing the study in March due to a software anomaly. The company paused the study about halfway through completion to correct an issue that could result in the system using an incorrect glucose value that had the potential to impact […]
- 1
- 2
- 3
- …
- 68
- Next Page »
